Labcorp Holdings Inc. $LH Shares Sold by AMI Asset Management Corp

AMI Asset Management Corp lessened its holdings in shares of Labcorp Holdings Inc. (NYSE:LH) by 2.2% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 178,762 shares of the medical research company’s stock after selling 4,014 shares during the quarter. Labcorp makes up about 2.5% of AMI Asset Management Corp’s portfolio, making the stock its 15th biggest holding. AMI Asset Management Corp owned approximately 0.22% of Labcorp worth $44,848,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Brighton Jones LLC purchased a new stake in Labcorp in the 4th quarter valued at about $991,000. Integrated Wealth Concepts LLC raised its holdings in Labcorp by 7.9% in the 1st quarter. Integrated Wealth Concepts LLC now owns 2,427 shares of the medical research company’s stock valued at $565,000 after buying an additional 177 shares during the period. Goldman Sachs Group Inc. raised its holdings in Labcorp by 52.2% in the 1st quarter. Goldman Sachs Group Inc. now owns 353,843 shares of the medical research company’s stock valued at $82,353,000 after buying an additional 121,304 shares during the period. Arrowstreet Capital Limited Partnership purchased a new stake in Labcorp in the 2nd quarter valued at about $5,873,000. Finally, First Trust Advisors LP raised its holdings in Labcorp by 83.2% in the 2nd quarter. First Trust Advisors LP now owns 86,046 shares of the medical research company’s stock valued at $22,588,000 after buying an additional 39,087 shares during the period. Institutional investors and hedge funds own 95.94% of the company’s stock.

Labcorp Stock Up 1.4%

Shares of NYSE:LH opened at $264.46 on Tuesday. The company has a debt-to-equity ratio of 0.60, a current ratio of 1.42 and a quick ratio of 1.23. The firm has a market capitalization of $21.79 billion, a PE ratio of 25.28, a price-to-earnings-growth ratio of 1.79 and a beta of 1.02. The firm’s 50-day moving average is $274.28 and its two-hundred day moving average is $268.56. Labcorp Holdings Inc. has a 1 year low of $209.38 and a 1 year high of $293.72.

Labcorp (NYSE:LH) last issued its quarterly earnings results on Tuesday, February 17th. The medical research company reported $4.07 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.95 by $0.12. The company had revenue of $3.52 billion for the quarter, compared to analyst estimates of $3.56 billion. Labcorp had a net margin of 6.28% and a return on equity of 16.16%. The business’s revenue for the quarter was up 5.6% compared to the same quarter last year. During the same period in the prior year, the firm earned $3.45 earnings per share. Labcorp has set its FY 2026 guidance at 17.550-18.250 EPS. Analysts predict that Labcorp Holdings Inc. will post 16.01 EPS for the current year.

Labcorp Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, June 11th. Investors of record on Friday, May 29th will be paid a dividend of $0.72 per share. This represents a $2.88 dividend on an annualized basis and a dividend yield of 1.1%. The ex-dividend date is Friday, May 29th. Labcorp’s dividend payout ratio is presently 27.53%.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on LH. JPMorgan Chase & Co. boosted their price objective on shares of Labcorp from $319.00 to $330.00 and gave the company an “overweight” rating in a report on Wednesday, February 18th. Robert W. Baird boosted their price objective on shares of Labcorp from $313.00 to $326.00 and gave the company an “outperform” rating in a report on Wednesday, February 18th. Wall Street Zen downgraded Labcorp from a “buy” rating to a “hold” rating in a research report on Saturday, April 4th. Morgan Stanley reiterated an “overweight” rating on shares of Labcorp in a research note on Tuesday, February 17th. Finally, Evercore reiterated an “outperform” rating and set a $300.00 price target on shares of Labcorp in a research note on Wednesday, April 8th. Eight equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $307.20.

Insider Activity

In related news, EVP Jonathan C. Meltzer sold 87 shares of the company’s stock in a transaction that occurred on Thursday, February 12th. The shares were sold at an average price of $290.42, for a total transaction of $25,266.54. Following the sale, the executive vice president directly owned 2,782 shares in the company, valued at approximately $807,948.44. This represents a 3.03% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Brian J. Caveney sold 1,500 shares of the company’s stock in a transaction that occurred on Tuesday, February 24th. The stock was sold at an average price of $286.31, for a total transaction of $429,465.00. Following the sale, the executive vice president owned 30,107 shares in the company, valued at $8,619,935.17. The trade was a 4.75% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 16,113 shares of company stock valued at $4,547,450 over the last three months. 0.84% of the stock is currently owned by corporate insiders.

Labcorp Company Profile

Laboratory Corporation of America Holdings, commonly known as Labcorp (NYSE: LH), is a global life sciences company that provides comprehensive clinical laboratory and drug development services. The company operates a broad network of laboratories, patient service centers and specialty testing sites to deliver diagnostic information and testing solutions that support patient care, clinical decision-making and population health initiatives.

Labcorp’s core businesses encompass clinical laboratory testing and pharmaceutical development services.